Thank you to the life sciences pioneers striving to make our most common and debilitating diseases a thing of the past.
Good news on the subject of medical breakthroughs is always welcome, and sometimes it can be particularly timely. Yesterday, NHS figures confirmed that prostate cancer has become the most common form of the disease in Britain, with approximately 50,000 cases diagnosed per annum. Today another announcement revealed that important progress is being made in prostate cancer treatment. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has been a leading light in research and development for seven decades. Founded in 1953, Janssen has never been afraid to take a step into new territory. In 1983 it became the first Western pharma company to open a factory in China.
Living longer, feeling better
Today came the news that the European Commission has approved marketing authorisation for the expanded use of the drug Erleada to include the treatment of metastatic hormone-sensitive prostate cancer. A Phase 3 study assessed use of Erleada in combination with androgen deprivation therapy and found that it improved patient survival rates by a striking 33%. Early signs are that Erleada may help delay disease progression and significantly prolong survival.
100,000 thank yous
Today’s announcement is excellent news for over 100,000 men living with this form of prostate cancer in Europe. It follows on from the decision by the FDA almost exactly two years ago to approve Erleada for treatment of non-metastatic forms of the disease in the United States. Not for the first time, Janssen’s success in a highly specialised field has crossed borders and continents, improving quality of life for a patient group that, as we’ve learned this week, is consistently growing. In their own words:
“We never stop imagining a future where the most challenging diseases are a thing of the past”.
Many of us imagine such a future; Janssen are doing something about it.
Conversis: helping you speak to the world
To find out more, contact us using the form below.
Please use the form to get in touch
or alternatively give us a call on: +44 (0)1869 255820